Association Between Baseline Disease Characteristics and Relapse-Free Survival in Patients With BRAF V600–Mutant Resected Stage III Melanoma Treated With Adjuvant Dabrafenib + Trametinib or Placebo

Main Article Content

Dirk Schadendorf
University Hospital Essen, Essen, and German Cancer Consortium, Heidelberg, Germany

Reinhard Dummer
University Hospital Z?rich Skin Cancer Center, Z?rich, Switzerland

Axel Hauschild
University Hospital Schleswig-Holstein, Kiel, Germany

Mario Santinami
Fondazione Istituto Nazionale Tumori, Milano, Italy

Victoria Atkinson
Princess Alexandra Hospital, Gallipoli Medical Research Foundation, University of Queensland, Woolloongabba, QLD, Australia

Mario Mandala
Papa Giovanni XXIII Cancer Center Hospital, Bergamo, Italy

Vanna Chiarion-Sileni
Melanoma Oncology Unit, Veneto Institute of Oncology IOV-IRCCS, Padova, Italy

James Larkin
The Royal Marsden NHS Foundation Trust, London, United Kingdom

Marta Nyakas
Oslo University Hospital, Oslo, Norway

Caroline Dutriaux
Centre Hospitalier Universitaire de Bordeaux, H?pital Saint-Andr?, Bordeaux, France

Andrew Haydon
The Alfred Hospital, Melbourne, VIC, Australia

Laurent Mortier
Universit? de Lille, INSERM U 1189, CHRU Lille, Lille, France

Caroline Robert
Gustave Roussy and Paris-Sud-Paris-Saclay University, Villejuif, France

Jacob Schachter
Ella Lemelbaum Institute for Immuno-Oncology and Melanoma, Sheba Medical Center, Tel Hashomer, and Sackler School of Medicine, Tel Aviv University, Tel Aviv, Israel

Christine-Elke Ortmann
Novartis Pharma AG, Basel, Switzerland

Egbert de Jong
Novartis Pharma AG, Basel, Switzerland

Edward Gasal
Novartis Pharmaceuticals Corporation, East Hanover, NJ

Richard Kefford
Macquarie University, Melanoma Institute Australia, Westmead Hospital, and The University of Sydney, Sydney, NSW, Australia

John M Kirkwood
Melanoma Program, UPMC Hillman Cancer Center, University of Pittsburgh, Pittsburgh, PA

Georgina V Long
Melanoma Institute Australia, The University of Sydney, and Royal North Shore and Mater Hospitals, Sydney, NSW, Australia

Keywords

melanoma, BRAF V600, dabrafenib, trametinib

Abstract

Abstract not available.

References

1. Hauschild A, et al. J Clin Oncol. 2018;36:3441-3449.

2. Long GV, et al. N Engl J Med. 2017;377:1813-1823.

3. Tafinlar (dabrafenib) [package insert]. East Hanover, NJ: Novartis Pharmaceuticals Corporation; 2018.

4. Mekinist (trametinib) [package insert]. East Hanover, NJ: Novartis Pharmaceuticals Corporation; 2018.

5. Tafinlar (dabrafenib) [summary of product characteristics]. Camberley, UK: Novartis Pharmaceuticals UK Ltd; 2018.
https://www.ema.europa.eu/en/documents/product-information/tafinlar-epar-product-information_en.pdf. Accessed April 18, 2019.

6. Mekinist (trametinib) [summary of product characteristics]. Camberley, UK: Novartis Pharmaceuticals UK Ltd; 2019.
https://www.ema.europa.eu/en/documents/product-information/mekinist-epar-product-information_en.pdf. Accessed April 18, 2019.

7. Dummer R, et al. ESMO 2018 [poster 1250P].

Article Sidebar

Poster PDF
Published
Nov 9, 2019
DOI https://doi.org/10.25251/skin.3.supp.53

Article Details

How to Cite
[1]
Schadendorf, D., Dummer, R., Hauschild, A., Santinami, M., Atkinson, V., Mandala, M., Chiarion-Sileni, V., Larkin, J., Nyakas, M., Dutriaux, C., Haydon, A., Mortier, L., Robert, C., Schachter, J., Ortmann, C.-E., de Jong, E., Gasal, E., Kefford, R., Kirkwood, J.M. and Long, G.V. 2019. Association Between Baseline Disease Characteristics and Relapse-Free Survival in Patients With BRAF V600–Mutant Resected Stage III Melanoma Treated With Adjuvant Dabrafenib + Trametinib or Placebo. SKIN The Journal of Cutaneous Medicine. 3, (Nov. 2019), S53. DOI:https://doi.org/10.25251/skin.3.supp.53.
Issue
Vol. 3 (2019): Supplemental Issue: Scientific Posters Presented at 2019 Fall Clinical Dermatology Conference®-Las Vegas
Section
Skin Cancer
Creative Commons License

This work is licensed under a Creative Commons Attribution 4.0 International License.

All authors retain copyright in their articles. All articles published open access allowing for immediate free access to the work and permitting any user to read, download, copy, distribute, print, search, or link to the full texts of articles, crawl them for indexing, pass them as data to software or use them for any other lawful purpose. Permitted reuse is defined by  the following user license:
 

Creative Commons Attribution (CC BY): lets others distribute and copy the article, to create extracts, abstracts, and other revised versions, adaptations or derivative works of or from an article (such as a translation), to include in a collective work (such as an anthology), to text or data mine the article, even for commercial purposes, as long as they credit the author(s), do not represent the author as endorsing their adaptation of the article, and do not modify the article in such a way as to damage the author's honor or reputation. 

Authors retain copyright in their work and license the publisher to publish the content. The publisher is the National Society for Cutaneous Medicine, with production and publishing support provided by OJS, Open Journal Systems,see https://pkp.sfu.ca/ojs/.

Prior to January 2022, authors transferred copyright to the National Society for Cutaneous Medicine. However, all articles are freely available to anyone in the world. There are no subscription fees, page charges, or article processing charges.

Similar Articles

1 2 > >> 

You may also start an advanced similarity search for this article.

Most read articles by the same author(s)

1 2 > >>